Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases
L39963
Genomic sequencing panels are covered for evaluation of blood or bone marrow in specific hematolymphoid conditions when results will inform management: newly diagnosed or relapsed/refractory AML candidates for treatment, AML patients with induction failure or transplant candidacy, and AML with documented relapse after prior response. Coverage is also allowed for suspected MDS/MDS-MPN with nondiagnostic standard assessments, newly diagnosed MDS stratified as intermediate risk (IPSS/IPSS-R) or RARS, and for MPNs when CML is excluded (BCR-ABL1 negative), including PMF risk stratification (non–DIPSS-Plus high-risk) and monitoring higher-risk myelofibrosis with progression on therapy; repeat testing in MDS after initial diagnosis and risk stratification is not covered.
"Genomic sequencing panel is reasonable for evaluation of blood or bone marrow in newly diagnosed acute myelogenous leukemia (AML) patients who are candidates for treatment, regardless of karyotype."